-

Deepcell Announces Presentation at 42nd Annual J.P. Morgan Healthcare Conference

MENLO PARK, Calif.--(BUSINESS WIRE)--Deepcell, a pioneer in artificial intelligence (AI)-powered single cell analysis to fuel deep biological discoveries, today announced that Maddison Masaeli, Ph.D., Co-Founder and Chief Executive Officer at Deepcell, will be presenting Wednesday, January 10, 2024 at the 42nd annual J.P. Morgan Healthcare Conference in San Francisco, Calif.

Event: J.P. Morgan 42nd Annual Healthcare Conference
Date: Wednesday, January 10th, 2024
Time: 3:00-3:25 p.m. PT

About Deepcell

Deepcell is a life science company which brings artificial intelligence to cell biology, unlocking a new field of high-dimensional biological discovery known as morpholomics. Through Deepcell’s AI-powered imaging and microfluidics solution, the REM-I Platform, the company is enabling a new scale of cell biology research and single cell analysis leveraging cellular morphology for unbounded discovery. Deepcell’s platform leverages its artificial intelligence model, the Human Foundation Model, to identify and sort cells based on morphological distinctions helping power basic and translational research and offering future applications in diagnostic testing and therapeutics targeting. The company was spun out of Stanford University in 2017 and has raised nearly $100 million in venture capital. It is based in Menlo Park, California. Learn more at www.deepcell.com or follow us on LinkedIn, Twitter, and YouTube.

Contacts

Deepcell


Release Summary
Deepcell Co-founder and CEO Maddison Masaeli, Ph.D., will present at the 42nd annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024.
Release Versions

Contacts

Social Media Profiles
More News From Deepcell

Deepcell Announces Successful Installation of the First Commercial REM-I Platform

MENLO PARK, Calif.--(BUSINESS WIRE)--Deepcell announces installation of first commercial REM-I platform. The company will present data at CYTO 2024 and Immunology 2024....

Deepcell Delivers Final Beta Testing Instruments Ahead of Full REM-I Platform Launch

MENLO PARK, Calif.--(BUSINESS WIRE)--Deepcell delivers beta testing instruments to Newcastle University and EMBL ahead of the full launch of the REM-I platform....

Deepcell Unveils Innovative AI-Powered Single Cell Morphology Data at Leading Scientific Meetings

MENLO PARK, Calif.--(BUSINESS WIRE)--Deepcell will present new scientific data at SLAS and AGBT meetings, as the company showcases key advantages the AI-enabled Deepcell REM-I Platform....
Back to Newsroom